Adenoviral vector technological platform

This platform enables endogenic synthesis of target proteins in the human body, executing different functions, including replacement therapy, stimulation of correct immune response and/or blocking of toxic (side-) effects of chemo- and radiotherapy. Such technology as a foundation enables the manufacturing of a new generation of vaccines and therapeutic medicines, including those to treat human flu, dengue fever, hepatitis C, as well as specialty drugs to treat toxic conditions in cancer patients and those with Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease).


  • The basic technology is the opportunity of usage of the neutralized and deprived adenoviruses. The embedded protein genes will enable the “introduction” to the immune system.

  • Adenoviruses enter the body, the genetic fragment reaches the cells, and the cells begin to produce the desired protein.

  • In the case of vaccines, this protein is a surface protein antigen, owing to which the immune system recognizes the virus.

  • In the case of therapeutic agents, synthesized proteins are necessary for treatment of the disease.

ADVANTAGES OF THE TECHNOLOGY (on the bases of influenza vaccines)

  • The production of such a vaccine does not require actual samples of strains of the virus from the WHO. We just need to know the genetic sequence of corresponding viruses.

  • This method allows halving the production period of a vaccine as compared to conventional technology.

  • This method is very cost-effective, unlike competing technologies.

  • The time required for specific antigen cleaning is dramatically reduced, and also provides safe environment without additional antigens and diminishes allergic reactions from patients.

  • This method also brings the opportunity to synthesize a wide range of therapeutic agents in the human body.